Friday, 30 Oct 2020

30,090

Total cases

649

New cases

19,757

Total discharged

246

Total deaths
0 New case(s)
OCT 29, 2020 (Source MOH)
EMBRACING NEW NORMS
21/08/2020 05:13 PM

KUALA LUMPUR, Aug 21  – Leading enterprise group in Cuba’s biotechnology and pharmaceutical industry BioCubaFarma reports having received permission to begin clinical trials of a Cuban candidate vaccine to prevent COVID-19, capable of producing a strong immune reaction to a SARS-CoV-2 infection.

Identified as FINLAY-FR-1, the vaccine project led by the Finlay Vaccine Institute, the Centre for Molecular Immunology – both affiliated with BioCubaFarma – with the collaboration of the University of Havana’s Chemical and Biomolecular Synthesis Laboratory, has satisfactorily concluded the drug’s development stage and pre-clinical studies in animals, producing the scientific findings required to support authorisation, by Cuba’s Centre for State Control of Medications, Medical Equipment and Devices (Cecmed), to conduct clinical trials. 

The announcement explained that this license allows for joint work with different institutions affiliated with the Ministry of Public Health to begin at this time, initiating “the clinical trial phase I-II, known as Sovereign, which will be followed by other clinical studies, before the vaccine is considered ready for use.”

“BioCubaFarma also reported that an industrial production strategy is being developed to build capacity with the goal of “having available the millions of doses needed to protect our population,” once the studies are concluded,” according to the report in Granma, the official newspaper of the Central Committee of the Cuban Communist Party, which was made available to Bernama by the Cuban Embassy in Malaysia.

Also of special interest is the fact reported that Cuba’s candidate vaccine is the 30th – the first in Latin America and the Caribbean – to receive authorisation for clinical trials, among the more than 200 under development around the world.

The Finlay Vaccine Institute, which submitted the license application, has more than 30 years of experience in developing vaccines, the announcement notes, stating, “The fact that the Institute has available platforms developed for other epidemics, specifically that developed for the meningitis epidemic in the 1980s, allowed these important results to be obtained.”

BioCubaFarma has described the progress made in the urgent effort to develop a vaccine here as a tribute to Comandante en Jefe Fidel Castro Ruz, visionary founder and promoter of the sector, while taking healthy pride in the results achieved, called on the entire population to maintain rigorous implementation of preventative measures to contain the epidemic as the country draws closer to producing our own vaccine.

-- BERNAMA

 

 

ABOUT US

Malaysian National News Agency
Wisma BERNAMA
No.28 Jalan BERNAMA
Off Jalan Tun Razak
50400 Kuala Lumpur
Malaysia

Tel : +603-2693 9933 (General Line)
Email : helpdesk[at]bernama.com

Categories

General
Business
Sports
Politics
World
Features
Thoughts
Infographics
Videos
Images
Exclusive Press

Copyrights

Disclaimer
Privacy Policy
Security Policy